>> Login
>> New User Registration
September 9, 2010
Overview | Faculty | Agenda | Hotel Accommodations | Free Registration
Symposium Co-Chairs


Jeffrey S. Weber, MD, PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair,
Department of Oncologic Sciences
University of South Florida
Tampa, FL


Alexander M. M. Eggermont, MD, PhD
Department of Surgical Oncology
Erasmus University Medical Center - Daniel den Hoed Cancer Center
Rotterdam, The Netherlands
EORTC Melanoma Group
Brussels, Belgium

Expert Faculty


F. Stephen Hodi, MD
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA


Jedd D. Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
Director, Immunotherapy Clinical Trials
Associate Attending Physician, Melanoma-Sarcoma Oncology Service
Associate Director, Ludwig Center for Cancer Immunotherapy
Associate Professor of Medicine, Weill Medical College of Cornell University

Bookmark and Share
The Next Generation of Therapy for Managing Melanoma Patients

The Next Generation of Therapy for Managing Melanoma Patients: CTLA-4 Blockade, Questions, Clinical Recommendations, and Clinical Cases

PLEASE NOTE:
Pre-registration is now available on a "stand-by" basis only. We have received the maximum number of 500 confirmed pre-registrants. We do expect that approximately 50 pre-registrants will not attend. So if you are interested in attending this symposium please register now as a "stand-by" pre-registrant. At 6:30PM on June 6, 2010 "standy-by" registrants can attend the symposium on a first-come basis. Thank you.

June 6, 2010 | Chicago IL
Hyatt Regency McCormick Place
Regency Ballroom Second Floor
6 PM - 6:30PM Registration and Dinner
6:30PM - 8:30PM CME Symposium

Taught by the top academic experts in melanoma this is THE symposium on melanoma that you should attend in 2010.
CO-CHAIRS

Jeffrey S. Weber, MD, PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair,
Department of Oncologic Sciences
University of South Florida
Tampa, FL

Alexander M. M. Eggermont, MD, PhD
Department of Surgical Oncology
Erasmus University Medical Center - Daniel den Hoed Cancer Center
Rotterdam, The Netherlands
EORTC Melanoma Group
Brussels, Belgium

   
•
 Overview
•
 Educational Statement of Need
•
 Disclosure
•
 Target Audience
•
 Learning Objectives
•
 CME Credit Information
•
 Agenda
•
 Faculty
•
 Hyatt Regency McCormick Place
•
 Register Now for Free
   
Agenda Back to Top
June 6, 2010 – Sunday
6:00PM - 6:30PM Registration and Reception
6:30PM Welcome and Introductions and CME Pre Test Jeffery S. Weber, MD, PhD
6:35PM Scientific and clinical data supporting the utilization of immunotherapy with CTLA-4 blockade for patients with melanoma Alexander M. M. Eggermont, MD, PhD
6:50PM

Strategies for managing the different melanoma patient response patterns to anti-CTLA-4 therapy

Four Clinical Scenarios, and Interactive Questions and Answers:

  1. Stable disease or regression
    How long should we continue therapy? Should we resect?
  2. Partial response or slow regression
    How long should we continue therapy? Should we modify therapy?
  3. Rapid CR or PR and new progression
    Should we change therapy or retreat with the same therapy? When should retreatment begin?
  4. Progression followed by regression
    Should we retreat with the same therapy or change therapy? When should retreatment begin?
 Jeffrey S. Weber, MD, PhD
7:10PM Questions from the audience Faculty and Audience
7:20PM Immune-related Adverse Events associated with CTLA-4 blockade --- Perspectives from clinicians F. Stephen Hodi, MD
7:40PM Questions from the audience Faculty and Audience
7:50PM Which biomarkers correlate with benefit of CTLA-4 blockade? Which should we use in the clinic today? Jedd D. Wolchok MD, PhD
8:10PM Questions from the audience Faculty and Audience
8:15PM Interactive challenging clinical case study: Correlating irAEs and Biomarkers with Outcomes. Patient management questions will be asked of the audience. Jeffery S. Weber, MD, PhD
8:25PM Closing remarks and post-activity clinical treatment strategy assessment questions utilizing interactive ARS Jeffery S. Weber, MD, PhD and Alexander M. M. Eggermont, MD, PhD
8:30PM AJOURN  
Educational Grants

Sincere appreciation is extended to Bristol-Myers Squibb for their generous commercial support of this educational meeting.

 
Bristol-Myers Squibb
© 2010 Oncology Learning Center
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Oncology Learning Center Web site reflect the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the Oncology Learning Center, the CME provider, or the pharmaceutical companies providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified medical or surgical oncologist, or hematologist should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any Oncology Learning Center materials. Click here for our Privacy Policy.